Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,579 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Central Nervous System Clear all
Active, not recruiting Phase 1 Interventional

Concurrent Azeliragon With Craniospinal Irradiation

NCT06724926
View directory record Official record
Conditions
Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
Interventions
Azeliragon, CSI
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

NCT01012609
View directory record Official record
Conditions
Brain Cancer
Interventions
cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 10, 2026, 4:14 PM EDT
Withdrawn No phase listed Observational

BTC Neuropsychological Database

NCT00873132
View directory record Official record
Conditions
Brain Tumor
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 10, 2026, 4:14 PM EDT
Suspended Not applicable Interventional

Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases

NCT05428852
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Laboratory Biomarker Analysis, Neurocognitive Assessment, Questionnaire Administration, Fitbit, Dietary Intervention
Other · Device · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

NCT01836549
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
Interventions
imetelstat sodium
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
12 Months to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 10, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706
View directory record Official record
Conditions
Glioma
Interventions
Abemaciclib, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years to 20 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Orange, California • Palo Alto, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting No phase listed Observational

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

NCT06273176
View directory record Official record
Conditions
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant, Brain Neoplasms, Brain Neoplasms, Adult, Malignant, Brain Neoplasms, Adult, Recurrent Adult Brain Tumor, Recurrent Glioblastoma
Interventions
Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
Procedure
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

NCT01371565
View directory record Official record
Conditions
Cushing's Disease, Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Hollywood, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases

NCT00328575
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Intensity-Modulated Radiotherapy (IMRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

NCT01664000
View directory record Official record
Conditions
Solid Tumors
Interventions
thioureidobutyronitrile
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors

NCT02129712
View directory record Official record
Conditions
Brain Tumor
Interventions
Cognitive training
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
7 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 10, 2026, 4:14 PM EDT
Completed No phase listed Observational

Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment

NCT01180881
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme

NCT00038493
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide and SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy

NCT02612155
View directory record Official record
Conditions
Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns
Interventions
Infusion of autologous cord blood, Placebo
Biological
Lead sponsor
Michael Cotten
Other
Eligibility
0 Hours to 6 Hours
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional

Mapping Draining Lymph Nodes in CNS Malignancies

NCT04096716
View directory record Official record
Conditions
Central Nervous System Neoplasms, Central Nervous System Tumor
Interventions
Tc-99m tilmanocept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVax, Balstilimab, Zalifrelimab
Biological · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

CONVIVO Endomicroscopy

NCT06087393
View directory record Official record
Conditions
Brain Tumor
Interventions
CONVIVO
Device
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

NCT02279992
View directory record Official record
Conditions
Glioma, Brain Neoplasms, Brain Metastasis
Interventions
Vardenafil, Carboplatin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 10, 2026, 4:14 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463
View directory record Official record
Conditions
Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
Interventions
Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

NCT04185038
View directory record Official record
Conditions
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma
Interventions
SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional Results available

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

NCT03705351
View directory record Official record
Conditions
Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
Interventions
Tumor Treating Fields, Temozolomide, Radiation Therapy
Device · Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Not listed No phase listed Observational

Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)

NCT01908179
View directory record Official record
Conditions
Metastatic Brain Tumor
Interventions
Not listed
Lead sponsor
Swedish Medical Center
Other
Eligibility
19 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting No phase listed Observational

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2034
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 4:14 PM EDT